Vedanta Biosciences to Present at Upcoming Investor Conferences
02 March 2021 - 11:00PM
Business Wire
Vedanta Biosciences, a leading clinical-stage microbiome company
developing a new category of oral therapies using rationally
defined bacterial consortia manufactured from clonal cell banks,
today announced that members of its executive team will present and
host one-on-one meetings at the following virtual investor
conferences:
Chardan 3rd Annual Microbiome Medicines Summit Date:
Monday, March 8, 2021 Presentation Time: 2:00 PM ET
H.C. Wainwright Global Life Sciences Conference Date:
Tuesday, March 9, 2021 Presentation Time: 7:00 AM ET
Credit Suisse 2021 Healthcare Innovators Series: Life
Sciences Private Company Event Date: Thursday, March 11, 2021
Presentation Time: 12:20 PM ET
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential
new category of oral therapies for immune-mediated diseases using
rationally defined bacterial consortia manufactured from clonal
cell banks. The Company’s approach bypasses the need to rely on
direct sourcing of donor fecal material of inconsistent
composition, thus overcoming challenges related to safety, quality,
and scalability that limit donor-derived approaches. The clinical
pipeline includes product candidates being evaluated for the
treatment of C. difficile infection, inflammatory bowel diseases,
advanced or metastatic cancers, and food allergy. These
investigational therapies are grounded in pioneering research –
published in leading journals including Science, Nature, and Cell –
that identified bacteria that induce a range of beneficial immune
responses. The Company’s platform includes what is believed to be
the largest library of bacteria derived from the human microbiome,
high throughput methods for bacterial consortium design, vast
datasets from human interventional studies, and state-of-the-art
capabilities for cGMP-compliant manufacturing of defined bacterial
consortia. Vedanta Biosciences controls a foundational intellectual
property portfolio covering compositions of matter and methods of
use for classes of bacteria that play key roles in human health.
Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC,
LSE: PRTC) and a global team of scientific co-founders who
pioneered the modern understanding of how the immune system and the
microbiome cross-talk.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302005408/en/
Investors and Media Chris Brinzey +1 617 835 9304
Chris.Brinzey@westwicke.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024